Core Insights - Ginkgo Bioworks' Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 [1] Company Overview - Ginkgo Bioworks specializes in engineering biology, providing customizable R&D solutions including protein engineering, nucleic acid design, and cell-free systems to accelerate innovation in therapeutics, diagnostics, and manufacturing [2] - The company offers modular laboratory automation through Ginkgo Automation, allowing scientists to focus on planning and analyzing experiments rather than manual pipetting [2] - Ginkgo Datapoints utilizes in-house automation to generate large lab datasets that support AI model development [2] - Ginkgo Biosecurity is focused on creating next-generation infrastructure and technologies for predicting, detecting, and responding to biological threats [2]

Core Insights - Ginkgo Bioworks has partnered with Deep Origin on a 4.5-year project funded by ARPA-H to develop a computational platform for drug safety [1][4] - The collaboration, named PREDICTS, aims to enhance pharmacological research through digital integration and clinical trial simulation [1][4] Company Overview - Ginkgo Bioworks specializes in engineering biology and offers customizable R&D solutions, including protein engineering and nucleic acid design [6] - The company utilizes its 'Datapoints' platform to generate large, structured datasets for AI model training, focusing on drug safety and efficacy [2][4] Project Details - The PREDICTS project will leverage Ginkgo's high-throughput capabilities to create detailed models of cellular responses to drug treatments [3][4] - The initiative will include various readouts such as cell type-specific toxicity endpoints and DRUG-seq transcriptomics [2] Strategic Importance - This partnership highlights Ginkgo's commitment to interdisciplinary collaboration and its expertise in generating large datasets for drug development [4] - The collaboration is expected to push the boundaries of multi-omics data generation, transforming drug discovery processes [4]

Core Insights - The presentation aims to provide an overview of the company's advancements in proteomics and the associated challenges in understanding the complexity of the proteome [1] - The focus is on the Proteus program, which represents the majority of the company's R&D investment, highlighting its significance in enhancing performance [1] Group 1: Technology and R&D - The company is investing heavily in the Proteus program, which is central to its current R&D efforts [1] - There are also modest investments in long-term technology development, indicating a balanced approach to immediate and future innovations [1] Group 2: Future Developments - Upcoming discussions will include plans to expand to 20 amino acids, with details on the timeline for achieving this goal [2]

Company Overview - Volition is a multinational company with laboratories in Belgium and San Diego, USA, focused on stabilizing and improving health outcomes for millions globally [4]. Technology Insights - The presentation highlights the Nu.Q technology, which is aimed at accelerating epigenetic drug development [3][4]. - Nucleosomes, the fundamental structural units of chromatin, are essential for compacting DNA into chromosomes, allowing the genome to fit into the cell nucleus [5].

Core Insights - Hypha Labs, Inc. has officially launched Phase II of its strategic partnership with Tryptomics, focusing on the development of functional mushroom technologies [1] - The collaboration combines Hypha's patented Mushroom Accelerator™ platform with Tryptomics' On-Site™ Science Services and contract R&D Metabolomics Pipeline [1] - This partnership aims to create proprietary varieties of bioreactor-optimized species and enhance quality assurance testing at Hypha Labs, thereby accelerating R&D cycles [1] Company Developments - The partnership with Tryptomics is expected to advance the future of at-home, pharmaceutical-grade mushroom wellness [1] - Hypha Labs is positioned to lead in the biotechnology sector by leveraging innovative technologies in functional mushrooms [1]

Core Insights - ZIVO Bioscience, Inc. is a biotech and agtech R&D company focused on developing therapeutic and nutritional products from proprietary algal cultures [1] Company Progress - The company has made significant progress in its operations and is optimistic about its future direction [1]

Core Viewpoint - Ginkgo Bioworks is settling multiple derivative actions with a total payment of $4,125,000 to be made by the Individual Defendants' Insurers, which is intended to benefit the company and its shareholders [5][7][10]. Summary by Sections Settlement Details - The settlement amount of $4,125,000 will be paid to Ginkgo within 30 days after the court enters the judgment [5]. - The settlement includes all fees and expenses of Plaintiffs' Counsel and Service Awards, which will be paid if approved by the court [5][8]. - Ginkgo will terminate a specific contract and implement corporate governance reforms for at least three years as part of the settlement [6]. Court Approval - A settlement hearing is scheduled for December 18, 2025, where the court will determine the fairness and adequacy of the settlement [9][10]. - Current Ginkgo stockholders have the right to appear at the hearing and object to the settlement or fee amounts [11][12]. Governance Reforms - The Board of Ginkgo has committed to adopting and maintaining comprehensive corporate governance and internal control reforms as part of the settlement [6][7]. - The Board believes the settlement confers substantial benefits to Ginkgo and its stockholders [7]. Legal Proceedings - The derivative actions are being settled in both the Northern District of California and Delaware Chancery Court [5][10]. - The settlement is part of a broader effort to address claims asserted in the derivative actions [6].

Core Viewpoint - PCI Biotech Holding ASA has decided to discontinue the development of its photochemical lysis (PCL) technology for viral vector manufacturing due to insufficient progress towards its 2025 goals [1][3] Group 1: Development Progress - The company aimed to demonstrate improved yield in mini benchtop bioreactors by 2025, but efforts have not yielded convincing results [1][2] - Additional initiatives were undertaken following the preliminary 2024 Interim Report and the Annual Report 2024, but these did not lead to satisfactory outcomes [2] Group 2: Project Risks and Financial Position - Insufficient progress has extended project timelines and increased resource requirements, raising the overall project risk to an unacceptable level [3] - As of June 2025, PCI Biotech's cash position was NOK 13.6 million, which is expected to sustain operations into Q4 2025, but there is uncertainty regarding the ability to secure additional financing [4] - The company is evaluating its future, considering options such as a potential sale, merger, or complete wind-down of operations [4]

Company Overview - Ginkgo Bioworks is focused on building a leading platform for cell programming and biosecurity [1] - The company offers customizable R&D packages, including protein engineering and nucleic acid design, to accelerate innovation in therapeutics, diagnostics, and manufacturing [3] - Ginkgo Automation provides modular laboratory automation solutions to enhance scientific productivity [3] - Ginkgo Biosecurity is developing next-generation infrastructure and technologies to address biological threats [3] Upcoming Events - Ginkgo Bioworks will host a presentation and Q&A session on August 7, 2025, to review its business performance for Q2 2025 [1] - The session will begin at 5:30 p.m. ET and will be available via webcast on the company's investor relations website [2] - Questions can be submitted in advance through social media or email [2]

Core Insights - The focus is on sustainable wealth growth through investments in R&D biotech [1] - The author expresses a personal beneficial long position in QURE shares, indicating confidence in the company's potential [1] Company and Industry Summary - The article emphasizes the importance of research and development in the biotechnology sector as a means to achieve sustainable investment returns [1] - The author highlights the relevance of their academic background in Cell Physiology and Bio-organic Chemistry to their investment strategy in biotech [1]